Diagnostic Efficacy Of Gene X-Pert/ MTB-RIF Assay And Its Implication For The Treatment Of MDR TB In Rural Medical College
Diagnostic Efficacy Of Gene X-Pert/ MTB-RIF Assay And Its Implication For The Treatment Of MDR TB
DOI:
https://doi.org/10.70284/njirm.v7i5.1134Keywords:
GENE XPERT MTB/RIF assay. Rifampicine resistance, MDR TB, HIV TBAbstract
Aims and objectives: To diagnose and treat the MDR Tuberculosis by XPERT MTB/RIF assay as early as possible so that transmission of infection can be minimized and To find out prevalence of MDR TB in our rural district of Maharashtra. Methods: This is a observational ,prospective study conducted over a period of 14 months ( Jan 15 to April 16 ) in the Dept. of Pulmonary Medicine, Shri Vasantrao Naik Gov.t Medical College, Yavatmal, Maharashtra. We have subjected 613 patients who fulfill the clinical criteria for RNTCP - MDRTB suspect 1.Treatment failure. 2. Retreatment case sputum positive at the end of 4 months, 3.Contact of known MDRTB case, 4.Sputum positive at diagnosis, retreatment case, 5. Any follow up sputum positive, 6.Other category (sputum negative retreatment cases), and 7. HIV-TB Cases. We have excluded all new cases (sputum positive, sputum negative and extrapulmonary cases ). With all precautions two sputum samples collected in the designated microscopy centre. One sample was subjected for routine ZN staining and other one for GENE X-PERT MTB/RIF assay. Result. Out of 613 MDR suspect subjects, 314 (51.23%) were found in the age group 30 to 50 which is economically productive age group. There were 428 (69.82%) male and 185 (30.18%) female. Out of total study patient 44 (7.18 %) were detected Rifampicin resistance by X-PERT MTB/RIF assay. Amongst MDR suspect criteria highest no (4.07 %) of Rifampicin resistant were found in Retreatment cases ( group 4 ) followed by 1.47 % in any follow up sputum positive ( group 5 ) , 0.65 % in sputum negative retreatment cases ( group 6), 0.32 % in treatment failure ( group 1 ) , 0.49 % in HIV TB cases (group7 and0.16 % in contacts of known MDR ( group 3) .There were 144 ( 23 .5 ) were co infected with HIV.TB. Conclusion: We conclude that GENE XPERT MTB /RIF assay has significant role in detecting Rifampicin resistance, patient can be started on treatment at the earliest thereby reducing morbidity, progression to XDR, mortality and transmission of MDR/XDR TB in the community can be minimized. However it has some shortcomings that it cannot detect resistance of other anti- tubercular drugs and atypical mycobacteria.[B.B.Bhadke NJIRM 2016; 7(5):33-39]
References
2. Boehme C. C. Rapid molecular detection of tuberculosis and rifampicin resistance. NEJM. 2010; 363:1005—1015.
3. Boehme C.C. et al, Feasibility, diagnostic accuracy, and effectiveness of decentralized use of the XPERT/MTB test for diagnosis of tuberculosis and multidrug resistance. A multicenter implementation study. Lancet 2011; 377;1495— 1505.
4. WHO. 2010. Global tuberculosis control: WHO report 2010. World HealthOrganization, Geneva, Switzerland
5. Munje et al Multidrug-resistant TB among previously treated TB cases: A retrospective study in Nagpur, IJT Volume 62, Issue 4, October 2015,Pages 207–210
GeneXpert Dx System Operator Manual. Cepheid Inc., Sunnyvale, CA, USA -2011.
6. El-Hajj et al. Detection of rifampin resistance in Mycobacterium tuberculosis in a single tube with molecular beacons. J. Clin. Microbiol.39, 4131-4137-2001.
7. Helb D., et al. “Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J. Clin. Micro. 48:229–237-2010.
8. GeneXpert Dx System Operator Manual. Cepheid Inc., Sunnyvale, CA, USA-2011.
9. WHO Anti tuberculosis drug resistance in the world. WHO Report No 3. Geneva:2004
10. Boum Y et al. Male Gender is independently associated with pulmonary tuberculosis among sputum and non-sputum producers people with presumptive tuberculosis in Southwestern Uganda. BMC Inf. Dis. 2014;14:638
11. Uwizeye CB et al. Tuberculosis may be underestimated in Rwandan women. IJTLD. 2011;15-6-:776–781
12. Neyrolles O et al. Sexual inequality in tuberculosis. Pub Med. 2009;6-12-:
13. Balasubramanian R et al. Gender disparities in tuberculosis: report from a rural DOTS programme in south India. IJTLD. 2004;8-3-:323–332
14. Djuretic T et al. Antibiotic resistant tuberculosis in the UK: Thorax 2002;57:477–482.482
15. Irish C et al, Database study of antibiotic resistant tuberculosis in the UK. BMJ 1999;318:497–498.
16. Migliori GB et al. Prevalence of resistance to anti-tuberculosis drugs: results of the 1998/99 national survey in Italy. IJTLD 2002;6:32–8.
17. Schwoebel V et al. Multidrug resistant tuberculosis in France 1992–94: two case-control studies. BMJ 1998;317:630–1.
18. Gillani et al. Study on drug-resistant tuberculosis and tuberculosis treatment outpatient with drug resistant tuberculosis in chest clinic outpatient department Int J Pharm Sci, 2012:Vol 4, Issue 2, 733-737
19. WHO. Roadmap for rolling out Xpert MTB/RIF for rapid diagnosis of TB and MDR-TB. December 6, 2010. Accessed May 4, 2011.
20. R.V. Chowgule et al, Pattern of secondary acquired drug resistance to antituberculosis drug in Mumbai, India–1991–1995 IJCDAS, 40 -1-1998, pp. 23–31
21. The majority of multidrug resistant tuberculosis were independently associated with life style & habitat of the patients, we found 20% smoker &13.33% alcoholic in multidrug resistant tuberculosis.
22. WHO Anti tuberculosis drug resistance in the world. WHO Report No 3. Geneva:2004
23. S.S. Negi et al, Drug resistance in tuberculosis in Delhi: a 2 year profile Jr. Comm.Dis., 35 -2- 2003, pp. 74–81
24. Sanchez-Padilla E et al. High prevalence of multidrug-resistant tuberculosis, Swaziland. Emerg Infect Dis .2012 Jan
25. WHO. Global Tuberculosis Control: A Short Update to the Report. Geneva, Switzerland; 2009.
26. E. L. Corbett et al., “The growing burden of tuberculosis: global trends and interactions with the HIV epidemic,†Archives of Internal Medicine, vol. 163-9-1009–1021, 2003.
27. H. C. Bucher et al., “Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials,†AIDS, vol. 13-4, 501–507, 1999.
28. P. A. Selwyn et al, “A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection,†NEJM vol. 320-9,545–550, 1989.
29. S. D. Lawn et al, “Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions,†Clinical Infectious Diseases, vol. 42-7,1040–1047, 2006.
30. K. DeRiemer et al, “Quantitative impact of human immunodeficiency virus infection on tuberculosis dynamics,â€AJRCCM, vol. 176-9,936–944, 2007.
31. Cohn DL et al. Drug-Resistant Tuberculosis: Review of the Worldwide Situation and the WHO/IUATLD Global Surveillance Project. Clinical Infectious Diseases 1997;24.
32. Fischl MA et al. An Outbreak of Tuberculosis Caused by Multiple-drug-resistant Tubercle Bacilli among Patients with HIV Infection. Annals of Internal Medicine 1992;117 177-83.
33. Nunn P et al. Surveillance of Resistance to Antituberculosis Drugs in Developing Countries. Tubercle and Lung Disease 1994;75 163-167.
34. Githui W et al. Cohort Study of HIV-positive and HIV-negative Tuberculosis, Nairobi, Kenya: Comparison of Bacteriological Results. Tubercle and Lung Disease 1992;73 203-209.
35. Robert J et al. Surveillance of Mycobacterium tuberculosis drug resistance in France, 1995–1997. IJTLD 2000;4:665–72.
36. Girardi E et al. Drug resistance patterns among tuberculosis patients in Rome, 1990–1992. SJIDS 1996;28:487–91.
37. Gordin FM et al. The Impact of Human Immunodeficiency Virus Infection on Drug Resistant Tuberculosis. AJRCCM 1996;154-5, 1478-1483.
38. Patel KB et al. Drug malabsorption and resistant tuberculosis in HIV-infected patients. NEJM 1995;332:336–7.
39. Suchindran S et al. Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review. Plos One. 2009;4:e5561.
40. Jeon DS et al. Treatment Outcome and Mortality among Patients with MDRTB in Tuberculosis Hospitals of the Public Sector. Infectious Diseases, Microbiology and Parasitology. Jr. of Korean Medical Science 2011;26 33-41.
41. Pablo Méndez A et al Global surveillance for antituberculosis drug resistance, 1994–1997. NEJM 1998;338:1641–1649.
42. Global TB control report 2012.December 17, 2014.
